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Abstract: Globally, lung cancer remains the most common cause of
cancer-related death. In recent years, it has become clear that
development of rational molecular targeted therapies is critical to
improve the outcomes of patients with lung cancer. A better under-
standing of the tumor biology is crucial to achieve this goal. Several
new findings in the field of tumor biology were presented at the 46th
Annual Meeting of the American Society of Clinical Oncology.
Novel genetic mutations were identified in pleural mesothelioma
using array-based technologies. Several studies on the development
and testing of new molecular diagnostic tests to detect epidermal
growth factor receptor tyrosine kinase mutations and EML4-ALK
(Echinoderm Microtubule-associated Protein like 4 Anaplastic
Lymphoma Receptor Tyrosine Kinase) fusion gene were presented
as well.
Key Words: Lung cancer, NSCLC, Tumor biology, EML4-ALK,
EGFR, Gene expression, K-ras, Mesothelioma.
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Lung cancer is the most common cause of cancer-relateddeath in the United States.1 More than half of these
patients present with advanced stage disease and systemic
therapy offer only modest benefits. The development of
rationally developed targeted therapies is likely to improve
the outcomes of patients with lung cancer significantly. Com-
prehensive understanding of the molecular aberrations in lung
cancer is crucial to achieve this goal. In recent years, the
introduction of genome-wide profiling technologies including
array-based comparative genomic hybridization, expression
arrays, single-nucleotide polymorphism arrays, and more re-
cently next generation sequencing has led to notable progress
in our understanding of lung cancer biology. Some of these
findings have had significant clinical implications such as the
identification of the EML4-ALK fusion gene in patients with
non-small cell lung cancer (NSCLC).2 Treatment with crizo-
tinib, a drug that targets this fusion gene results in striking
responses in appropriately selected patients with NSCLC.3
Nevertheless, this fusion gene is identified in less than 5% of
all patients with NSCLC. Further studies are required to
identify other such unique molecular changes that can be
effectively targeted to treat patients with lung cancer. In the
recently concluded 46th Annual Meeting of the American
Society of Clinical Oncology, results from several studies
related to lung cancer tumor biology or biomarkers were
presented. We have identified some of the key presentations
and summarized their findings in this brief review.
EPIDERMAL GROWTH FACTOR RECEPTOR
Somatic mutations in the kinase domain of epidermal
growth factor receptor (EGFR) mutations, most commonly in
exon 19 or 21, are the most reliable predictors for response to
the EGFR tyrosine kinase inhibitors (TKIs), gefitinib and
erlotinib.4,5 K-ras is an important downstream mediator of
EGFR signaling and is mutated in approximately 20% of
patients with adenocarcinoma of the lung. As K-ras muta-
tions are associated with decreased response rates and inferior
outcomes in patients treated with EGFR TKIs, both EGFR
and K-ras mutations are frequently evaluated as predictors
for outcomes in patients with NSCLC.6
A retrospective study of 2080 patients with lung ade-
nocarcinoma was conducted to evaluate the frequency of
EGFR mutations and correlation with clinical variables.7
EGFR mutations were found in 264 of 540 (49%) of never
smokers, 149 of 1188 (13%) of former smokers, and 19 of
352 (5%) of current smokers. Mutations were also more
common in women compared with men (23% versus 17%).
The fact that EGFR mutations are present in men and in those
with a history of smoking raises the question whether all
patients with NSCLC should be tested for EGFR mutations.
Several polymerase chain reaction (PCR)/sequencing-
based EGFR mutation detection assays are commercially
available.8 The turnaround time for many of these tests is
several days, and the quality of the tumor samples may also
limit their ability to detect the mutation. In a search for a
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rapid and sensitive assay for the detection of EGFRmutations
using routine pathology specimens, 219 patients were tested
for L858R mutation using real-time allele-specific PCR and
for exon 19 deletions by length analysis of PCR products.9
EGFR alterations were detected in 35 patients (16%), includ-
ing 21 with exon 19 deletion (9.6%) and 14 with L858R
mutation (6.4%). These procedures, performed in paraffin-
embedded sections, had a rapid turnaround time of 24 hours.
In a retrospective study to evaluate the prognostic
implication of EGFR and K-ras mutations in never smokers
with lung adenocarcinoma, the clinical outcomes for 175
patients with early stage (stages I–IIIA) and 362 patients with
advanced stage (IIIB or IV), there was a significant difference
according to mutation status.10 Among patients with early
disease, 3-year survival was significantly better in those with
EGFR mutation compared with wild type (86% versus 71%;
p  0.02) and in wild-type K-ras compared with mutant
K-ras (81% versus 36%; p  0.001). In advanced disease,
although EGFR mutation was associated with improved sur-
vival (48% versus 29%; p  0.01), the small survival im-
provement in wild-type K-ras was not statistically significant
(40% versus 35%; p  0.3).
Danenberg et al.11 evaluated 838 specimens from pa-
tients with colorectal cancer and 1165 from patients with
NSCLC for K-rasmutations and 649 specimens from patients
with NSCLC for EGFR mutations. K-ras mutations were
more common in patients with colorectal cancer than patients
with NSCLC (39% versus 23%; p  0.001). Previous studies
have shown that exposure to tobacco smoke determines the
type of Kras mutations identified in the tumor tissue.12,13
K-ras mutations in tobacco smokers are more likely to be
G3T transversions, whereas in never smokers G3A tran-
sition mutations are seen more frequently. The type of Kras
mutation was also analyzed in this study by Danenberg and
colleagues. As expected, K-rasmutations with tobacco smok-
ing-related G3T transversions were more frequent in pa-
tients with NSCLC than patients with colorectal cancer (61%
of all K-ras mutations versus 39%; p  0.001). In the 447
tumor samples tested for both EGFR and K-ras mutations,
the mutations were mutually exclusive in most, with only
four specimens containing both mutations.
MET/VASCULAR ENDOTHELIAL GROWTH
FACTOR/INSULIN-LIKE GROWTH FACTOR
Overexpression of MET (Mesenchymal Epithelial
Transition Factor) has been reported in NSCLC, and the fact
that it is phosphorylated in these tumors suggests that it is
activated in NSCLC.14,15 Resistance to EGFR-TKIs has also
been associated with MET amplification.16
Cancer and Leukemia Group B conducted a study to
correlate MET expression, phosphorylation, mutation, and
amplification with survival in patients with resected adeno-
carcinoma. This project will also evaluate the correlation with
other markers (EGFR and P53 mutational status and level of
expression, KRAS (Kristen Rat Sarcoma viral oncogene ho-
molog) exon 2 mutational status, and epidermal-mesenchy-
mal transition) and their impact on clinical outcomes. Interim
results from 20 patients identified that the majority of them
(95%) had high expression ofMET by immunohistochemistry
(IHC). Moreover, mutational analysis was performed in 40
patients, and previously unreported MET mutations were
identified in three (7.5%) patients. Extended results and
correlation with survival endpoints are awaited.17
Insulin-like growth factor receptor (IGF-1R) is associ-
ated with tumorigenesis, metastasis, and resistance to therapy
in experimental models.18 Nevertheless, a large phase III trial
failed to demonstrate any benefit in unselected patients with
NSCLC with the addition of an IGF-1R directed monoclonal
antibody.19
Tissue microarrays of tumor tissue from patients with
NSCLC were used to analyze protein expression patterns of
IGF and Src genes.20 The Src pathway has been shown to be
a potential therapeutic target in NSCLC.21 Tumor samples
from two independent tissue banks (n  352 and n  458)
were incorporated in the tissue microarrays. Expression lev-
els of IGF-1R, IGF-1, IGF-2, phospho IGF-1R/IR, and phos-
pho Src were measured by immunofluorescence (p  0.05).
The expression of these genes except for IGF-1 was signifi-
cantly higher in patients with squamous cell carcinoma than
patients with adenocarcinoma (p  0.05). Similarly, the
expression of these genes was higher in tumor specimens
from current smokers than from never smokers (p  0.05).
Results from this study also suggest that phospho Src expres-
sion may be an independent prognostic factor in patients with
NSCLC, hazard ratio 1.02 (1.003–1.038) p  0.02. Both
IGF-1R and Src kinase pathways seem to be active in NSCLC
particularly so in squamous cell carcinoma of the lung.
Optimal patient selection and choosing appropriate agents
that inhibit these promising pathways continue to be chal-
lenging.
EML4-ALK
EML4-ALK is the first fusion gene discovered in
NSCLC.2 The genes EML4 and ALK are both located in
chromosome 2 and the fusion results from an inversion within
the chromosome. The EML4-ALK fusion gene is unique to
NSCLC and has gain of function properties.2,22,23 The EML4-
ALK fusion gene is more frequently identified in younger
patients with adenocarcinoma than older patients with other
tumor histologies.22,24–28 There is also a significant associa-
tion with never smokers, and they seem to be mutually
exclusive with EGFR and K-ras mutations. Crizotinib is a
dual kinase inhibitor with activity against ALK kinase and
C-met. In a recent phase I trial, patients with EML4-ALK-
positive NSCLC treated with crizotinib had an overall re-
sponse rate of 64% and disease control rate of 90%.3 It is
important to develop robust and easy to use diagnostic meth-
ods to detect EML4-ALK fusion gene when screening patients
for treatment with crizotinib. Both fluorescent in situ hybrid-
ization (FISH) and PCR methods have been used to detect
EML4-ALK, though FISH is being used in ongoing clinical
trials with crizotinib.
Several groups have analyzed archived NSCLC tumor
samples to describe the clinical characteristics and outcomes
of patients with NSCLC harboring the EML4-ALK fusion
gene.29–33 The frequency of EML4-ALK fusion gene ranged
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between 2 and 5%, consistent with previous publications
(Table 1). Furthermore, it was detected only in patients with
adenocarcinoma histology.31–33 In addition, efforts were
made to develop newer diagnostic methods to detect EML4-
ALK fusion gene.
An IHC-based assay using antibodies specific to the
ALK kinase has been developed to detect EML4-ALK fusion
gene.30 To determine the accuracy of this method, FISH
testing was done on a third of these tumor samples. There was
complete correlation between IHC and FISH results. In an-
other study, IHC was used to detect EML4-ALK, but the
results were not compared with FISH or PCR.33 Nevertheless,
the results from this study on the prevalence and clinicopath-
ologic characteristics of patients with EML4-ALK are consis-
tent with previously reported studies. A multiplex reverse-
transcriptase-PCR technique was reported to be effective in
detecting EML4-ALK fusion gene in formalin-fixed paraffin-
embedded (FFPE) samples using probes specifically designed
to detect EML4-ALK fusion in FFPE samples.29 Positive
controls with cell lines that harbor EML4-ALK variants and
negative control with A549 cell line that does not have the
fusion gene were used to validate this PCR method. The
authors report 100% specificity and sensitivity more than
99.9% in detecting the EML4-ALK fusion gene using this
technique.
Even though current clinical trials are using FISH to
detect EML4-ALK rearrangement, there are advantages to
further developing and implementing the PCR and IHC
assays. In addition, to identifying the fusion gene, PCR
methods can quantify the fusion transcript and specify the
type of EML4-ALK variant in a particular tumor sample. The
IHC-based assay would be easy to use and can provide rapid
diagnosis in relatively small tissue samples.
TUMOR GENOME PROFILING IN
MESOTHELIOMA
Mesothelioma is a neoplasm arising in serosal cavities,
and it is associated with asbestos exposure.34,35 Mesothelioma
is characterized by frequent deletion of p16 (80%) gene and
loss of heterozygosity in the neurofibromatosis type 2 gene
(60%).36,37 Patients with mesothelioma usually present with
advanced stage disease, and the median survival ranges
between 9 and 12 months.38 Global genomic profiling was
performed on 53 pleural mesothelioma tumors using expres-
sion and copy number arrays followed by targeted resequenc-
ing to identify new genetic changes.39 Based on the global
profiling, 25 genes were identified and were sequenced in the
tumor samples. Of these 25 genes, mutations involving 15
genes were identified by sequencing in the tumor tissue and
comparison with corresponding normal tissue was done for
the majority of the samples (Table 2). Mutations involving
the BRCA (breast cancer)-associated protein 1 (BAP-1) gene
were identified in 12 (22.6%) tumor samples. It was con-
firmed by PCR in samples harboring the mutation. Validation
was done in an additional 68 tumors samples, and BAP-1
mutations were identified in 13 (19%) tumors. The exact role
of BAP-1 mutation is not known though it has been previ-
TABLE 1. Clinical Characteristics of Patients with EML4-ALK Fusion Gene
Kudo et al.33 Varella-Garcia et al.32 Soda et al.31 Danenberg et al.29 Rimkunas et al.30
N 492 447 384 130 656
Method IHC FISH RT-PCR RT-PCR IHC/FISH
ALK positive 9 (1.8%) 12 (2.7%) 20 (5.2%) 6 (4.3%) 27 (4.1%)
Median age, yr (range) 53 (26–75) 66 (60–79) 50.9 (27–80) — —
Gender
Male 3 (0.9%) 7 (1.6%) 5 (2%) — —
Female 6 (3.7%) 5 (1.1%) 15 (10.9%) — —
Histology
Adeno 9 (3.5%) 12 (2.7%) 20 (7.9%) — —
Squamous 0 0 0 — —
Smoking status
Never smokers 6 4 (0.9%) — — —
Smokers 3 8 (1.8%) — — —
IHC, immunohistochemistry; FISH, fluorescent in situ hybridization; RT-PCR, reverse-transcriptase polymerase chain reaction.
TABLE 2. List of Mutated Genes in Pleural Mesothelioma
Genes No. of Mutations (%)
BAP1 12 (22.6)
NF2 11 (19.6)
LATS2 4 (7.1)
RICTOR 4 (7.1)
TP53 4 (7.1)
CHEK2 2 (3.6)
LATS1 2 (3.6)
RB1 2 (3.6)
CDH5 1 (1.9)
CDKN3 1 (1.9)
ING1 1 (1.9)
PTPRD 1 (1.9)
RASSF1 1 (1.9)
SDHB 1 (1.9)
SMARCB1 1 (1.9)
BAP1, BRCA-associated protein 1; NF2, neurofibromatosis type 2.
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ously identified in a small number of lung adenocarcinoma
samples.40 There was no correlation between BAP-1 muta-
tions status and survival, histology, or asbestos exposure.
Further experiments are required to clarify the functional role
of BAP-1 mutation in pleural mesothelioma.
MOLECULAR CLASSIFICATION OF NSCLC
Histologic classification plays an important role in
determining treatment choices for patients with NSCLC. Data
from recent clinical trials have shown that only patients with
nonsquamous histology are candidates for treatment with
pemetrexed or bevacizumab.41,42 Nevertheless, the medical
oncologist is often faced with the dilemma of treating patients
with tumors classified as NSCLC otherwise unspecified. In an
effort to address this perennial problem, a protein-based assay
was developed to differentiate between squamous and ade-
nocarcinoma histologies in patients with NSCLC. In a train-
ing set of 343 NSCLC tumor samples, the expression of a
panel of 24 proteins was compared between adenocarcinoma
and squamous cell carcinoma using quantitative immunoflu-
orescence.43 A four-protein classifier was developed from this
panel to differentiate between adenocarcinoma and squamous
histologies. The pathologist’s diagnosis was the gold standard
against which the assay was compared. The assay had a
sensitivity of 96% and specificity of 93% in the training set.
The assay was then validated by blinded analysis in two
independent cohorts: a retrospectively collected cohort (n 
197) and a prospectively collected cohort (n  235). The
assay had a sensitivity of 92% and specificity of 97% to
differentiate between squamous versus adenocarcinoma his-
tology in the retrospective cohort. In the prospective cohort,
the assay yielded a sensitivity and specificity of 96% and
97%, respectively. These results show the feasibility of de-
veloping molecular tests that can aid in histologic classifica-
tion of NSCLC. As histology guides treatment decision in
patients with NSCLC, such a test can be a valuable addition
to the clinician.
SUMMARY
The identification of BAP-1 mutation in pleural me-
sothelioma is a novel discovery, and further studies are
required to clarify the functional role of this mutation. The
fact that EML4-ALK is found exclusively in patients with
adenocarcinoma is an important finding that would help the
clinician screening patients for ongoing clinical trials on
crizotinib and identify patients who are likely to harbor the
fusion gene. Using IHC to detect the EML4-ALK fusion
gene (if validated in further studies) could be useful in cases
where sufficient tissue is not available for FISH or PCR. The
development of a robust assay using PCR for detection of the
EGFR-tyrosine kinase mutation from FFPE samples would
be useful in the clinic to rapidly and accurately identify the
presence of the mutation. The role of IGF, Src, vascular
endothelial growth factor, and MET as therapeutic targets or
as biomarkers requires further investigation.
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